GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1421-1428

  Spano, Jean Philippe ^a   Vano, Y ^a   Vignot, S ^a   De La Motte Rouge, T ^a   Hassani, L ^a   Mouawad, R ^a   Menegaux, F ^a   Khayat, D ^a   Leenhardt, L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Gemcitabine; Oxaliplatin; Refractory thyroid carcinoma; Relevant therapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; IODINE 131; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; THYROID NEOPLASMS;

EID: 84872827576     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0070-2     Document Type: Article

References (32)

1. Colonna M, Grande E, Jonasson JG, Eurocare Working G. Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (eurocare-3 study). Eur J Cancer. 2006;42:2598-608.
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20:525-31.
3. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee. Thyroid. 2004;14:1056-60.
4. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-11.
5. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148-56.
6. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-9.
7. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010;15:146-56.
8. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10:303-10.
9. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974; 290:193-7.
10. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40:210-3.
11. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-60.
12. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-9.
13. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen KF. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study. J Clin Oncol. 2008;26:4708-13.
14. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11:962-72.
15. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161: 923-31.
16. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-84.
17. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 2000;128: 1059-65. discussion 1065-1056.
18. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25:4-12.
19. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 20,20-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44:117-23.
20. Cancer therapy evaluation program. Common toxicity criteria, version 2.0.2. dctd, nci, nih, dhhs. NIH; 1998. http://ctep.cancer. gov/.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am StatAssoc J. 1958;53:457-81.
23. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, De Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a gercor and giscad phase III trial. J Clin Oncol. 2005;23:3509-16.
24. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C. Gemcitabine combined with oxaliplatin (gemox) in advanced biliary tract adenocarcinoma: a gercor study. Ann Oncol. 2004;15:1339-43.
25. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol. 2002;13:1479-89.
26. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J. Gemcitabine plus oxaliplatin (gemox) in patients with advanced hepatocellular carcinoma (hcc): results of a phase II study. Cancer. 2007; 109:1384-90.
27. Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, Andre T, Louvet C. Firstline simplified gemox (s-gemox) versus classical gemox in metastatic pancreatic cancer (mpa): results of a gercor randomized phase ii study. Bull Cancer. 2009;96:E18-22.
28. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, Pacini F. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160-5.
29. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349-57.
30. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31-42.
31. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The m. D. Anderson experience. J Clin Endocrinol Metab. 2010;95:2588-95.
32. Leboulleux S, Bastholt L, Krause TM, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised double blind phase II trial. International thyroid conference, Paris, France; 2010, Abstr OC-023.